BASEL, Switzerland, Feb. 15 /CNW Telbec/ - Neuro-Biotech Corp.
(PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its shareholders
additional details about the unsolicited offer received on February 9,
2011. The offer was received from Auric Pharma Science, a well
established company based out of Madrid, Spain, that has been operating
since 1972. The offer provided is for the purchase of all the
outstanding shares of MRES at a price of $0.15 per share.
As announced this morning, management has deemed it in the best interest
of the Company to accept such an offer based on the documents provided
by Auric. However, there are outstanding conditions that have yet to be
met in order to complete the due diligence. Such details should be
addressed by end of the day, on February 25, 2011.
For more information on Neuro-Biotech Corp or to contact a company
representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions, and
that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or obligation
to update or revise forward-looking information, whether as a result of
new information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
SOURCE Neuro-Biotech Corp.
For further information:
Dr. Claude Poulin
41 61 500 05 16